NCT06965881 - Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2025

Conditions

Tuberous Sclerosis Complex (TSC)Focal Cortical DysplasiaOther Neurological Disorders

Interventions

DRUG

Radiprodil with Carbamazepine

Participants will receive oral doses of Radiprodil in the range of 7.5mg to 30mg along with oral doses of Carbamazepine in the range of 100mg to 300mg twice daily over a period of 27 days.

DRUG

Radiprodil with Itraconazole

Participants will receive oral doses of Radiprodil in the range of 7.5mg to 15mg along with oral doses of Itraconazole 200mg twice daily over a period of 21 days.

Trial Locations (2)

3004

RECRUITING

Nucleus Network Pty Ltd, Melbourne

4006

RECRUITING

Q-Pharm Pty Ltd, Brisbane